Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 11/20 | 0.57 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.55 |
| ▸ | CDK4 | P11802 | 5/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 4/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.52 |
| ▸ | CCND1 | P24385 | 4/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.52 |
| ▸ | CCND2 | P30279 | 2/20 | 0.52 |
| ▸ | CCND3 | P30281 | 2/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073131 | 0.89 | IGF1R (0.54) | IGF1RTNK2CDK4AURKACDK1 | |
| SCHEMBL4065005 | 0.89 | CDK4 (0.55) | IGF1RTNK2CDK4CDK1CCNB1 | |
| SCHEMBL13812805 | 0.88 | CDK4 (0.52) | IGF1RTNK2CDK4AURKACDK1 | |
| SCHEMBL4067264 | 0.81 | CCND3 (0.59) | CDK4CCND1CCNE1CDK2CCND2 | |
| SCHEMBL13705502 | 0.79 | ADORA3 (0.53) | IGF1RCDK4AURKACDK1CCNB1 | |
| SCHEMBL4068561 | 0.77 | CDK4 (0.59) | CDK4CDK1CCNB1CCND1CDK2 | |
| SCHEMBL28775720 | 0.77 | JAK3 (0.57) | IGF1RCDK4CDK1CCNB1CCND1 | |
| SCHEMBL11346255 | 0.76 | IGF1R (0.69) | IGF1RTNK2SYK | |
| SCHEMBL10138638 | 0.74 | FGFR1 (0.49) | IGF1RTNK2 | |
| SCHEMBL14594179 | 0.74 | JAK2 (0.54) | CDK4AURKACDK1CCNB1CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590341-B1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1590341-A1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004065378-A1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | CDK4, CCNA1, CCNI | IGF1R 639/4885TNK2 115/4885CDK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.